sialyl-Tn antigen-keyhole-limpet hemocyanin conjugate

01/01/2002 - "Phase II trials suggest prolongation of survival of advanced breast cancer patients who generate high titers of antibody to Theratope. "
01/01/2003 - "In June 2002, Biomira stated that it believes the market size for THERATOPE in the US, Europe and Japan to be approximately 184000 patients for the indication of metastatic breast cancer, of which the US would be 100000, Europe 75000 and Japan 9000. "
01/01/2003 - "Merck KGaA has acquired a worldwide licence to THERATOPE for treatment of breast cancer. "
01/01/2013 - "Adding STn-KLH to endocrine therapy may improve clinical outcomes with few adverse effects for women with metastatic breast cancer."
01/01/2003 - "The US FDA has granted fast-track status tranted fast-track status to THERATOPE for development as an adjunct to first-line combination chemotherapy in responding patients with metastatic breast cancer. "

07/18/2017 - "Vaccination with 4-KLH, in which the two N-acetyl groups of STn are substituted with N-fluoroacetyl groups, could remarkably prolong the survival of tumor-bearing mouse and resulted in a significant reduction in tumor burden of lungs compared with STn-KLH (1-KLH). "
11/01/2001 - "When LN cells were injected subcutaneously in the presence of STn-KLH-sensitized lymphocytes, tumor growth was decreased. "
01/01/2003 - "Biomira is developing a therapeutic cancer vaccine [THERATOPE] for treatment of breast and other cancers. "
11/01/2003 - "Combinations of CYC and cancer vaccines such as autologous tumor cells, Melacine, large multivalent immunogen (LMI), and Theratope have been tested with some success in humans for more than a decade. "
08/01/2003 - "Combinations of CY and cancer vaccines such as autologous tumor cells, Melacine, large multivalent immunogen (LMI), and Theratope have been tested with some success in humans for more than a decade. "

02/01/2003 - "Between 1995 and 2000, 70 patients (16 with stage II/III breast cancer, 17 with stage III/IV ovarian cancer, and 37 with stage IV breast cancer) were treated with 2 different formulations of STn-KLH. "
06/01/2000 - "Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine."
01/01/1999 - "Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine."
06/01/1996 - "Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with Theratope sialyl-Tn-KLH (keyhole limpet hemocyanin) cancer vaccine emulsified in Detox adjuvant. "
06/01/2000 - "We conclude that the THERATOPE STn-KLH cancer vaccine is well tolerated in breast and ovarian cancer patients after autologous transplant and, while not statistically significant, the trends in data support the concept that THERATOPE vaccine may decrease the risk for relapse and death and thus warrants further study. "

01/01/2003 - "For the indication of colorectal cancer, the total market population for THERATOPE is expected to be 183000 patients, of which the US has been estimated at 100000, Europe 75000 and Japan 9000."
01/01/1996 - "Breast and colorectal cancer patients who had the highest anti-OSM antibody titers, determined 4 weeks after the fourth immunization with STn-KLH (post-4 ASI), survived longer than the patients who had lower post-4 active specific immunotherapy (ASI) anti-OSM antibody titers. "
09/01/1995 - "Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients."
01/01/1996 - "The humoral immune response of 85 metastatic breast, ovarian, and colorectal cancer patients was analyzed after immunization with THERATOPE STn-KLH (KLH, keyhole limpet hemocyanin) cancer vaccine emulsified in DETOX adjuvant. "

01/01/2011 - "injection of 100 μg STn-KLH plus adjuvant (treatment group) or 100 μg KLH plus adjuvant (control group) at weeks 0, 2, 5, and 9. Subsequently, STn-KLH without adjuvant or KLH without adjuvant was then administered monthly for 4 months, and then quarterly until disease progression, without cyclophosphamide. "